Neurocrine Biosciences
NBIX
#1287
Rank
$13.54 B
Marketcap
$134.62
Share price
1.10%
Change (1 day)
43.99%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total debt

Total debt on the balance sheet as of March 2024 : $0.51 B

According to Neurocrine Biosciences 's latest financial reports the company's total debt is $0.51 B. A companyโ€™s total debt is the sum of all current and non-current debts.

Neurocrine Biosciences - Total debt on balance sheet (from 2001 to 2024)

Total debt by year

Year Total debt Change
2023-12-31$0.42 B62.95%
2022-12-31$0.26 B-40.3%
2021-12-31$0.44 B6.82%
2020-12-31$0.41 B-16.79%
2019-12-31$0.49 B27.54%
2018-12-31$0.38 B5.11%
2017-12-31$0.36 B
2009-12-31$11.53 M-25.12%
2008-12-31$15.39 M936.14%
2007-12-31$1.48 M-97.23%
2006-12-31$53.64 M-9.7%
2005-12-31$59.4 M-10.17%
2004-12-31$66.12 M81.5%
2003-12-31$36.43 M359.14%
2002-12-31$7.93 M39.53%
2001-12-31$5.68 M

Total debt for similar companies or competitors

Company Total debt differencediff. Country
$68.70 B 13,322.15%๐Ÿ‡บ๐Ÿ‡ธ USA
$74.00 B 14,356.14%๐Ÿ‡บ๐Ÿ‡ธ USA
$26.21 B 5,020.41%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.73 B 44.12%๐Ÿ‡บ๐Ÿ‡ธ USA
$18.57 M-96.37%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.28 B-44.24%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.7 M-99.86%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.13 B 1,099.33%๐Ÿ‡ฌ๐Ÿ‡ง UK